comprehensive -WSS

comprehensive

author：focus 2025-08-28 08:41:02 - browse：339

U.S. Sen. Bernie Sanders sets his hands on two chairs as two people set up a board displaying a "price of drugs" chart behind him — politics coverage from STAT — Sen. Bernie Sanders has used his leadership of a Senate committee to pressure drugmakers to lower their prices. Kevin Dietsch/Getty Images

WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him.

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs.

Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. He’s threatened subpoenas, held a prominent nominee hostage, and initiated investigations to get his way. It’s a sharp departure from the modest, bipartisan ambitions that more disciplined, discreet leaders of the committee have taken in years past, and sets the bar for how much can be accomplished using the full extent of the bully pulpit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Why Medicare shouldn’t cover every FDA

hotspot

WSS

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Pancreatic cancer early detection could be helped by AI

Time to name cancers by genetics, not organ of origin, expert says

Do digital therapeutics have a future in medicine?

Quicker fix for pulse oximeters urged during FDA public meeting

General Catalyst, Summa Health deal will turn on physician buy

explore

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why you shouldn’t ask, “What country has the best health care?”

Jerome Adams on the need for new antivirals for Covid

Even great ERs can’t make up for American health disparities

ChatGPT in medicine: STAT answers readers' burning questions

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Heart attack and stroke risk calculators need revising

Biden administration opens offers in Medicare drug price negotiations

What does generative AI mean for health care? We asked experts

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

entertainment

Medicare drug price negotiation’s day in court

Even great ERs can’t make up for American health disparities

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Covid misinformation case heads to Supreme Court

10 reasons why health care startups fail

entertainment

hotspot

focus

hotspot